MA33429B1 - Production de poliovirus à titres élevés pour la production de vaccins - Google Patents

Production de poliovirus à titres élevés pour la production de vaccins

Info

Publication number
MA33429B1
MA33429B1 MA34534A MA34534A MA33429B1 MA 33429 B1 MA33429 B1 MA 33429B1 MA 34534 A MA34534 A MA 34534A MA 34534 A MA34534 A MA 34534A MA 33429 B1 MA33429 B1 MA 33429B1
Authority
MA
Morocco
Prior art keywords
production
poliovirus
high quantity
vaccine
cells
Prior art date
Application number
MA34534A
Other languages
Arabic (ar)
English (en)
Inventor
John Alfred Lewis
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of MA33429B1 publication Critical patent/MA33429B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne un procédé de production de poliovirus consistant à : a) fournir une culture cellulaire en suspension sans sérum, les cellules étant des cellules PER.C6, b) infecter lesdites cellules avec le poliovirus avec une densité cellulaire comprise entre 2 x 10
MA34534A 2009-07-16 2010-07-08 Production de poliovirus à titres élevés pour la production de vaccins MA33429B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27103809P 2009-07-16 2009-07-16
EP09165620 2009-07-16
PCT/EP2010/059796 WO2011006823A1 (fr) 2009-07-16 2010-07-08 Production de poliovirus à titres élevés pour la production de vaccins

Publications (1)

Publication Number Publication Date
MA33429B1 true MA33429B1 (fr) 2012-07-03

Family

ID=41412431

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34534A MA33429B1 (fr) 2009-07-16 2010-07-08 Production de poliovirus à titres élevés pour la production de vaccins

Country Status (33)

Country Link
US (4) US8546123B2 (fr)
EP (1) EP2454364B1 (fr)
JP (1) JP5845178B2 (fr)
KR (1) KR101548790B1 (fr)
CN (1) CN102482647B (fr)
AP (1) AP3140A (fr)
AR (1) AR077314A1 (fr)
AU (1) AU2010272685B2 (fr)
BR (1) BR112012000942B8 (fr)
CA (1) CA2763091C (fr)
CO (1) CO6491042A2 (fr)
CU (1) CU20120006A7 (fr)
DK (1) DK2454364T3 (fr)
EA (1) EA020563B1 (fr)
ES (1) ES2484093T3 (fr)
HK (1) HK1164922A1 (fr)
HR (1) HRP20140597T1 (fr)
IL (1) IL217465A (fr)
MA (1) MA33429B1 (fr)
MX (1) MX2011012648A (fr)
MY (1) MY183385A (fr)
NZ (1) NZ596880A (fr)
PE (1) PE20120571A1 (fr)
PL (1) PL2454364T3 (fr)
PT (1) PT2454364E (fr)
RS (1) RS53377B (fr)
SG (1) SG177655A1 (fr)
SI (1) SI2454364T1 (fr)
SM (1) SMT201400079B (fr)
TN (1) TN2011000628A1 (fr)
TW (1) TWI477606B (fr)
WO (1) WO2011006823A1 (fr)
ZA (1) ZA201108271B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647985C (fr) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation Virus de la grippe recombinants a haut titre pour vaccins
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
BRPI0921651A2 (pt) 2008-11-03 2015-08-18 Crucell Holland Bv Método para produzir adenovírus recombinante, e partículas virais, e, biorreator
SG177655A1 (en) 2009-07-16 2012-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
US9109013B2 (en) 2009-10-26 2015-08-18 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
AU2014215025B2 (en) 2013-02-05 2018-08-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cell lines for virus production and methods of use
WO2014135651A1 (fr) 2013-03-08 2014-09-12 Crucell Holland B.V. Vaccin acellulaire contre la coqueluche
WO2014142433A1 (fr) 2013-03-13 2014-09-18 고려대학교산학협력단 Souche cellulaire ayant une capacité de production de virus accrue et procédé pour la produire
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
RS57864B1 (sr) 2013-06-17 2018-12-31 De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo Postupci za sprečavanje agregacije virusnih komponenti
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US20160053281A1 (en) * 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
CN106232800B (zh) 2014-03-25 2020-07-03 泰尔茂比司特公司 介质的被动替代
AU2015276235B2 (en) 2014-06-17 2021-02-18 Janssen Vaccines & Prevention B.V. Cold-Adapted-Viral-Attenuation (CAVA) and novel attenuated Poliovirus strains
US10526393B2 (en) 2014-06-18 2020-01-07 Immunomax Co., Ltd. Method for promoting virus infection and increasing virus production, by using cell line having lost BST2 gene functions
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP3172317B1 (fr) 2014-07-24 2019-05-01 Janssen Vaccines & Prevention B.V. Procédé de purification du virus de la poliomyélite à partir de cultures cellulaires
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017004592A1 (fr) 2015-07-02 2017-01-05 Terumo Bct, Inc. Croissance cellulaire à l'aide de stimuli mécaniques
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
WO2017205667A1 (fr) 2016-05-25 2017-11-30 Terumo Bct, Inc. Expansion cellulaire
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10372100B2 (en) * 2016-08-29 2019-08-06 Ge Healthcare Bio-Sciences Corp. Manufacturing system for biopharmaceutical products
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
CN107723279B (zh) * 2017-10-18 2020-11-10 成都远睿生物技术有限公司 一种缺陷型腺病毒AdC68-GP的培养方法
WO2019155492A1 (fr) * 2018-02-07 2019-08-15 Bharat Biotech International Limited Procédé de purification et d'inactivation d'entérovirus et compositions de vaccin obtenues à partir de celui-ci
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2020223699A1 (fr) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Réplication améliorée du virus de la grippe pour l'élaboration de vaccin
WO2020229581A1 (fr) 2019-05-16 2020-11-19 Janssen Vaccines & Prevention B.V. Méthodes pour induire une réponse immunitaire sûre contre le virus de la polio
WO2021041624A2 (fr) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Virus de la grippe recombinants à ha stabilisé pour réplication dans des oeufs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
EP0833934B2 (fr) 1995-06-15 2012-08-15 Crucell Holland B.V. Systemes d'empaquetage pour adenovirus recombinant chez l'homme, destine a la therapie genique
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
EP1103610A1 (fr) 1999-11-26 2001-05-30 Introgene B.V. Production de vaccins de lignées de cellules mammifère immortalisées
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP1256803A1 (fr) 2001-05-07 2002-11-13 Crucell Holland B.V. Méthodes pour l'identification des composés antiviraux
AU2003288273A1 (en) * 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
NZ539813A (en) * 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
CN101328473B (zh) * 2003-05-09 2012-05-02 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
CN1930281A (zh) 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
EA010057B1 (ru) 2004-08-27 2008-06-30 Панацея Биотек Лтд. Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
ATE523205T1 (de) * 2004-10-14 2011-09-15 Crucell Holland Bv Prime-boost-impfstoffe gegen malaria
CN100500827C (zh) * 2004-11-26 2009-06-17 中国医学科学院医学生物学研究所 用人胚肺二倍体细胞培养繁殖脊髓灰质炎病毒的方法
US20100144620A1 (en) * 2006-11-16 2010-06-10 Crucell Holland B.V. Complementation of factor xi deficeincy by factor v mutants
SG177655A1 (en) * 2009-07-16 2012-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
KR20120070015A (ko) 2010-12-21 2012-06-29 (주)창조바이오텍 알파-피넨을 유효성분으로 포함하는 스쿠티카충 구제용 조성물

Also Published As

Publication number Publication date
AP3140A (en) 2015-02-28
CO6491042A2 (es) 2012-07-31
CU20120006A7 (es) 2012-10-15
EA020563B1 (ru) 2014-12-30
MX2011012648A (es) 2012-01-12
TN2011000628A1 (en) 2013-05-24
US20130052224A1 (en) 2013-02-28
AP2012006075A0 (en) 2012-02-29
US20140242670A1 (en) 2014-08-28
US20130273106A1 (en) 2013-10-17
EP2454364A1 (fr) 2012-05-23
US20110027317A1 (en) 2011-02-03
EA201270173A1 (ru) 2012-06-29
NZ596880A (en) 2013-10-25
BR112012000942B8 (pt) 2021-05-25
DK2454364T3 (da) 2014-07-21
IL217465A0 (en) 2012-02-29
SMT201400079B (it) 2014-09-08
CN102482647B (zh) 2015-12-16
CA2763091A1 (fr) 2011-01-20
AR077314A1 (es) 2011-08-17
AU2010272685A1 (en) 2011-12-08
HK1164922A1 (en) 2012-09-28
CA2763091C (fr) 2019-07-23
MY183385A (en) 2021-02-18
PE20120571A1 (es) 2012-06-06
CN102482647A (zh) 2012-05-30
ES2484093T3 (es) 2014-08-11
KR20120033334A (ko) 2012-04-06
WO2011006823A1 (fr) 2011-01-20
EP2454364B1 (fr) 2014-04-23
PL2454364T3 (pl) 2014-09-30
SI2454364T1 (sl) 2014-08-29
JP5845178B2 (ja) 2016-01-20
JP2012532616A (ja) 2012-12-20
HRP20140597T1 (hr) 2014-09-12
TWI477606B (zh) 2015-03-21
IL217465A (en) 2016-05-31
BR112012000942B1 (pt) 2020-10-27
US8546123B2 (en) 2013-10-01
PT2454364E (pt) 2014-07-04
ZA201108271B (en) 2012-07-25
TW201118173A (en) 2011-06-01
AU2010272685B2 (en) 2015-02-26
US9022240B2 (en) 2015-05-05
RS53377B (en) 2014-10-31
BR112012000942A2 (pt) 2016-03-15
SG177655A1 (en) 2012-02-28
KR101548790B1 (ko) 2015-08-31

Similar Documents

Publication Publication Date Title
MA33429B1 (fr) Production de poliovirus à titres élevés pour la production de vaccins
CY1116226T1 (el) Χρηση toy rna για επαναπρογραμματισμο σωματικων κυτταρων
MX346523B (es) Mejoras de cultivos celulares.
NZ703137A (en) Cells for producing recombinant iduronate-2-sulfatase
SG196784A1 (en) Stem cell cultures
MX2021000210A (es) Metodos y productos para transfeccion de celulas.
MA32827B1 (fr) Procede de sequestration de carbone
MX2011011402A (es) Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos.
MX2012002270A (es) Ensayos de cribado in vivo.
MX2010001319A (es) Metodo para producir proteinas heterogeneas.
MX2021009554A (es) Produccion de virus en cultivos celulares.
IN2012DN00384A (fr)
MX2014006570A (es) Cocteles de enzimas preparados a partir de cultivos mezclados.
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
PL407694A1 (pl) Fotobioreaktor do biosekwestracji CO<sub>2</sub> z unieruchomioną biomasa glonów lub sinic
NZ599479A (en) Improved reverse genetics methods for virus rescue
MX2009007790A (es) Mejora del crecimiento celular.
ES2351296B8 (es) Cepas de s. cerevisiae capaces de crecer en medios con melibiosa, estaquiosa y rafinosa.
EA201100845A1 (ru) СПОСОБ ПОЛУЧЕНИЯ pH-СТАБИЛЬНЫХ ПОКРЫТЫХ ОБОЛОЧКОЙ ВИРУСОВ
MX337070B (es) Método para preparar un conjugado klh-egfrviii.
MX353243B (es) Metodo para incrementar la secrecion de proteinas recombinantes.
MX2021014131A (es) Plantas de melon resistentes al mildiu.
AR091960A1 (es) Celulas fúngicas que producen menores cantidades de peptaiboles
JP2014223038A5 (fr)